Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Minghetti, L.
Right arrow Articles by Pocchiari, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Minghetti, L.
Right arrow Articles by Pocchiari, M.
Related Collections
Right arrow Prion
Neurology 2002;58:127-129
© 2002 American Academy of Neurology
Brief Communications

Increased CSF levels of prostaglandin E2 in variant Creutzfeldt–Jakob disease

L. Minghetti, PhD, F. Cardone, PhD, A. Greco, DSc, M. Puopolo, DStat, G. Levi, MD, A. J.E. Green, MD, R. Knight, FRCP(Ed); and M. Pocchiari, MD

From the Laboratories of Pathophysiology (Drs. Minghetti, Greco, Puopolo, and Levi) and Virology (Drs. Cardone and Pocchiari), Istituto Superiore di Sanità, Rome, Italy; and National CJD Surveillance Unit (Drs. Green and Knight), Western General Hospital, Edinburgh, United Kingdom.

Address correspondence and reprint requests to Prof. Maurizio Pocchiari, Laboratory of Virology, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy; e-mail: pocchia{at}iss.it

The concentration of the cyclooxygenase product prostaglandin E2 was sixfold higher in CSF samples from 18 cases of variant Creutzfeldt–Jakob disease (CJD) than in a group of eight subjects with other noninflammatory neurologic diseases, and comparable to those found in a group of six patients affected by diseases with a known inflammatory component. This finding suggests that cyclooxygenase activity may have a role in variant CJD pathogenesis, as previously reported in sporadic CJD.




This article has been cited by other articles:


Home page
 NeurologyHome page
P. Sanchez-Juan, A. Green, A. Ladogana, N. Cuadrado-Corrales, R. Saanchez-Valle, E. Mitrovaa, K. Stoeck, T. Sklaviadis, J. Kulczycki, K. Hess, et al.
CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease.
Neurology, August 22, 2006; 67(4): 637 - 643.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
M Combrinck, J Williams, M A De Berardinis, D Warden, M Puopolo, A D Smith, and L Minghetti
Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease
J. Neurol. Neurosurg. Psychiatry, January 1, 2006; 77(1): 85 - 88.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
C. Bate and A. Williams
Role of glycosylphosphatidylinositols in the activation of phospholipase A2 and the neurotoxicity of prions
J. Gen. Virol., December 1, 2004; 85(12): 3797 - 3804.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Bate, M. Salmona, L. Diomede, and A. Williams
Squalestatin Cures Prion-infected Neurons and Protects Against Prion Neurotoxicity
J. Biol. Chem., April 9, 2004; 279(15): 14983 - 14990.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.